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Abstract
Background: Procalcitonin (PCT) is a biomarker used to assess systemic inflammation, infection, and sepsis and to
optimize antimicrobial therapies. Its role in the in the differential diagnosis between candidemia and bacteremia is
unclear. The aim of this systematic review was to summarize the current evidence about PCT values for
differentiating candidemia from bacteremia.
Methods: PubMed and EMBASE were searched for studies reporting data on the diagnostic performance of serum PCT
levels in intensive care unit (ICU) or non-ICU adult patients with candidemia, in comparison to patients with bacteremia.
Results: We included 16 studies for a total of 45.079 patients and 785 cases of candidemia. Most studies claimed to
report data relating to the use of PCT values for differentiating between candidemia and bacteremia in septic patients in
the intensive care unit. However, the studies identified were all retrospective, except for one secondary analysis of a
prospective dataset, and clinically very heterogeneous and involved different assessment methods. Most studies did show
lower PCT values in patients with candidemia compared to bacteremia. However, the evidence supporting this
observation is of low quality and the difference seems insufficiently discriminative to guide therapeutic decisions. None of
the studies retrieved actually studied guidance of antifungal treatment by PCT. PCT may improve diagnostic performance
regarding candidemia when combined with other biomarkers of infection (e.g., beta-D-glucan) but more data is needed.
Conclusions: PCT should not be used as a standalone tool for the differential diagnosis between candidemia and
bacteremia due to limited supporting evidence.
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Background
Early diagnosis of candidemia is challenging [1–3]. The
absence of sensitive and specific clinical signs and symp-
toms and radiological findings as well as the prolonged
time of blood culture growth hamper early identification
of candidemia [2, 4]. Adding to this is the need to differ-
entiate between bacterial and fungal infections, which
often have similar clinical manifestations. For these rea-
sons, risk factor clinical characteristics, scoring systems,
and microbiological techniques (culture- and non-
culture-based) are all being used to optimize early treat-
ment and reduce unnecessary antifungal therapy [4–13].
Procalcitonin (PCT) has been proposed as a useful
tool to characterize systemic inflammation, infection,
and sepsis [14–16]. Findings from several randomized
controlled trials indicate that the use of a PCT-guided
antibiotic treatment algorithm (i.e., PCT guidance) is
likely to reduce antibiotic exposure in septic patients,
without an adverse effect on health outcomes [17]. PCT
production is promoted by lipopolysaccharides and cyto-
kines, which are expressed in pro-inflammatory condi-
tions [18]. Although some non-bacterial inflammatory
conditions increase PCT levels, bacterial infections typic-
ally show higher PCT serum concentration [14, 18, 19].
Some studies reported lower PCT serum levels in patients
with candidemia compared to bacteremia [20, 21]. Al-
though the mechanism for this finding is unclear, patients
with invasive candidiasis showed signs of impaired inflam-
matory response, immune cell exhaustion, and reduced
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production of positive co-stimulatory molecules [22–24].
Thus, the serum levels of PCT may differ in patients with
bacterial and Candida infections [1, 20, 21]. The aim of
this systematic review was to summarize the current evi-
dence about PCT values for differentiating candidemia
from bacteremia.
Methods
Search strategy and selection process
For the purpose of this review, a search was conducted in
PubMed and EMBASE (see Additional files 1 and 2). The
terms used included “Candida” OR “fungi” AND “Procal-
citonin” (see full search strategy in Additional file 1). We
considered only articles published in peer-review journals
in the English language. We excluded conference proceed-
ings and case reports.
We selected studies reporting data on the values and
diagnostic performance of PCT in intensive care unit
(ICU) or non-ICU nonimmunosuppressed adult patients
with microbiologically confirmed candidemia in com-
parison to patients with bacteremia. We also included
studies in which data about PCT where reported
separately for patients with candidemia from those with
other fungal infections. If several samples of PCT were
taken, we selected the value of the first available PCT
sampled during the diagnostic process.
Two searches were run: the first in 5 October 2018 and
the last in 20 February 2019. Two authors (AC, GM) inde-
pendently screened all titles and abstracts to select poten-
tially relevant papers. Papers selected for full review also
underwent screening of their list of references by the same
authors to identify additional potential studies of interest.
Discrepancies between the two reviewers on relevance at
any stage were adjudicated by two other authors (ES, AG).
Papers selected for full review underwent data extraction
if both reviewers (AC, GM) agreed on their relevance. In
case of doubt at any stage, we contacted the correspond-
ing authors of the manuscripts. Figure 1 describes paper
inclusion/exclusion process.
Results
Characteristics of the included studies
The searches yielded overall 1175 articles (see Add-
itional files 1 and 2). Among these, 43 were selected for
Fig. 1 PRISMA flow chart of the systematic search
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full review but only 16 were ultimately selected for in-
clusion. These 16 studies included overall 45.079 adults
and yielded of 785 cases of candidemia. Of these studies,
10 specifically referred to ICU patients. Twelve of the 16
included studies had at least sepsis as inclusion criteria;
three studies did not report this information; in one
study, the majority of patients were at least septic, but
sepsis was not an inclusion criterion (Table 1). All stud-
ies were retrospective, except for one secondary analysis
of a prospectively collected dataset.
Table 1 presents data from the included studies, includ-
ing study design, patient characteristics, microbiological
findings, assays used for dosing, and the information given
on the diagnostic performance of PCT. Following qualita-
tive synthesis of the data, a decision was made to not to
proceed to meta-analysis because of the heterogeneity
found in patient populations (study and control groups)
and the assays used, as well as the amount of missing data
(i.e., large risk of bias). Instead, we hereby summarize the
evidence from included studies.
PCT levels for differentiating candidemia from bacteremia
Studies in the ICU
In a retrospective cohort study, Charles et al. evaluated
50 non-surgical septic ICU patients with bloodstream in-
fection (BSI). They found significantly lower PCT levels
in patients with candidemia (median 0.65 ng/ml [range
0.08–1.56], n = 15) compared to those with bacteremia
(median 9.75 ng/ml [range 1.00–259.5]). PCT levels <
5.5 ng/ml had a negative predictive value (NPV) of 100%
and a positive predictive value (PPV) of 65% for Can-
dida spp. sepsis [25].
Martini et al. prospectively studied 48 post-surgery
septic ICU patients. PCT levels were lower in candide-
mia (0.71 [IQR 0.5–1.1], n = 17) than in bacterial BSI
(12.9 [IQR 2.6–81.2]) [26].
Brodska et al. retrospectively studied 166 ICU septic
patients with BSI. Significantly higher PCT levels were
observed with Gram-negative pathogens (8.90 ng/ml
[IQR 1.88–32.60]) than with Gram-positive pathogens
(0.73 ng/ml [IQR 0.22–3.40]) or Candida spp. (0.58
[IQR 0.35–0.73], n = 5) [28].
Cortegiani et al. retrospectively studied PCT levels and
blood cultures in 182 ICU patients with sepsis (60%
post-surgical). Significantly lower levels of PCT were
found in cases with candidemia (0.99 ng/ml [IQR 0.86–1.34],
n = 22) than in cases with bacterial BSI (16.7 ng/ml [IQR
7.52–50.2]) or mixed BSI (4.76 ng/ml [IQR 2.98–6.08]). A
PCT cut-off value ≤ 6.08 ng/ml demonstrated a PPV of
63.9% and a NPV of 96.3% for identifying Candida spp. [30].
Miglietta et al. retrospectively studied 145 septic ICU
patients (mostly medical). Significantly lower PCT levels
were found in patients with candidemia (0.55 [IQR
0.36–0.91], n = 33) than in patients with bacteremia
(10.2 [IQR 1.28–25.3]). However, PCT was unable to dif-
ferentiate between candidemia and a systemic inflamma-
tory response without infection [32].
Yan et al. retrospectively evaluated 414 septic patients in
the ICU and emergency department with positive blood
culture [37]. They found a median PCT level of 1.11
[0.41–2.24] in 19 candidemias caused by C. albicans, 0.79
[IQR 0.4–1.7] in 5 candidemias by C. parapsilosis and 5.37
[0.29–10.45] in 2 candidemias by C. tropicalis.
Bassetti et al. retrospectively compared 258 ICU pa-
tients with positive blood culture (cases) to 213 controls.
In cases with candidemia (n = 11), the serum PCT con-
centration was 2.1 ng/ml (SD 1.8), significantly lower
than in Gram-positive or Gram-negative BSI [38].
Thomas-Rüddel et al. performed a secondary analysis
of a prospectively collected dataset involving 4858 septic
patients with at least one related organ dysfunction from
the ICUs of 40 hospitals [40]. PCT values at sepsis onset
were analyzed in patients with bacteremia or candidemia
but mixed infections were excluded. PCT values were
significantly higher in patients with Gram-negative (26
ng/ml [IQR 7.7–63.1]) than Gram-positive bacteremia
(7.1 ng/ml [IQR 2.0–23.3]) or candidemia (4.7 ng/ml
[IQR 1.9–13.7], n = 63).
Studies in wards or including hospitalized patients
Pieralli et al. retrospectively compared 64 cases with sepsis
due to Candida spp. and 128 cases with sepsis due to bac-
teria in 3 internal medicine wards [36]. PCT levels were
significantly lower in candidemia than in bacteremia (0.73
ng/ml [IQR 0.26–1.85] and 4.48 ng/ml [IQR 1.10–18.26],
respectively). The best cut-off was 2.5 ng/ml, with a NPV
of 98.3% and a PPV of 15.1%.
Oussalah et al. performed a cross-sectional, single-
center study of 35.343 patients with suspected BSI [33].
Significantly lower PCT levels were found in patients with
candidemia (1.0 ng/ml [IQR 0.3–2.7], n = 256) compared
to patients with Gram-positive (1.3 ng/ml [IQR 0.3–6.9])
and Gram-negative BSI (2.2 ng/ml [IQR 0.6–12.2]). How-
ever, these levels were also higher than those in patients
with negative blood culture (0.3 ng/ml [IQR 0.1–1.1]).
Li et al. retrospectively evaluated PCT levels in 292 sep-
tic patients in a single center. PCT levels were lower in
patients with sepsis caused by C. parapsilosis (0.60 [IQR
0.14–2.06], n = 8) or by C. albicans (1.00 [IQR 0.30–2.65],
n = 8) than in patients with Gram-negative sepsis (7.47
[IQR 1.09–41.26]). No difference was found between pa-
tients with sepsis caused by Candida spp. versus Gram-
positive bacteria (0.48 [IQR 0.15–2.16]) [34].
Leli et al. prospectively observed 1.949 patients (89%
from medical ward) and found that a cut-off value of
1.6 ng/ml differentiates Gram-negative BSI from candi-
demia and a cut-off value of 1.3 ng/ml differentiates
Gram-positive BSI from candidemia (n = 24). Patients
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with candidemia presented with a median PCT value of
0.5 ng/ml [IQR 0.4–1] [31].
Murri et al. retrospectively studied 401 patients hospi-
talized with sepsis and BSI. Those with candidemia (n =
55) had significantly lower PCT levels (0.8 ng/ml, SD
4.9) than those with Gram-positive (2.8 ng/ml, SD 16.6)
or Gram-negative BSI (10.4 ng/ml, SD 26.9) [39]. In
mixed infections, PCT levels were 2.1 ng/ml (SD 10.0)
and 0.1 ng/ml (SD 0.1) for Candida spp. with Gram-
positive and Gram-negative bacteria, respectively.
PCT use in association with other biomarkers
PCT has been also evaluated in combination with other
biomarkers for improving performance in diagnosis of
IC [29, 35].
Giacobbe et al. retrospectively assessed the combin-
ation of PCT and beta-D-glucan (BDG) in 166 critically
ill ICU patients for early differentiation between
bacteremia and candidemia [35]. Compared to patients
with bacteremia, the levels of PCT were lower (median
0.76 vs. 4.32 ng/ml, p < 0.001) and those of BDG were
higher (median > 500 vs. < 80 pg/ml, p < 0.001) in pa-
tients affected by candidemia. Combining the standard
BDG cut-off level (≥ 80 pg/ml) with the rounded optimal
PCT cut-off level (< 2 ng/ml) yielded a higher PPV for
identifying the presence of candidemia than the PPV of
either test alone. Held et al. similarly reported that the
combination of BDG and PCT increased specificity
(from 89.4 to 96.2%), but this was accompanied by loss
of sensitivity (from 86.7 to 51.7%) for candidemia in 56
hospitalized patients [29].
Fu et al. found that the combination of PCT (cut-off
8.06 ng/ml), CRP (cut-off value 116mg/l), and IL-6 (cut-
off 186.5 pg/ml) increased the sensitivity and specificity
for early diagnosis of candidemia (n = 23) and its distinc-
tion from Gram-positive/negative bacteremia (AUC to
0.912) in 85 ICU septic patients [27]. However, PCT
showed the best diagnostic performance, when com-
pared to CRP or IL-6.
Discussion
In this systematic review of the value of PCT for differ-
entiating between candidemia and bacteremia, we found
that PCT has been studied in only 785 cases of candide-
mia. We limited our analysis to adult nonimmunosup-
pressed patients with bloodstream infections related to
Candida spp. to reduce clinical heterogeneity.
Most of the studies identified evaluated the use of PCT
for differentiating between candidemia and bacteremia in
septic patients in the ICU. We found no study specifically
evaluating PCT levels as a tool for monitoring the effect
of antifungal treatment.
Although most of these studies showed lower PCT values
in patients with candidemia compared to bacteremia, the
evidence supporting this observation is of low quality.
Moreover, this difference seems to be insufficiently discrim-
inative to guide therapeutic decisions.
PCT may improve diagnostic performance when com-
bined with other biomarkers of infection. Of note, the
association with BDG may be of interest due its wide-
spread use and specific role in this setting [2, 41]. How-
ever, this finding requires additional confirmation.
Our systematic review has several limitations. We
could not proceed with meta-analysis because the stud-
ies identified were clinically very heterogeneous, involv-
ing different assessment methods and comparators. This
may limit the impact of our findings but should be
mostly seen as a limitation of the available evidence ra-
ther than of the review. Another limitation is the inabil-
ity to separate the results and conclusions according to
septic state (e.g., sepsis, septic shock). However, most
studies did use sepsis as inclusion criteria or included
mostly septic patients (13 out of 16 studies). We were
unable to select studies where a surrogate of fungal in-
fection (e.g., beta-D-glucan) was sampled alongside PCT
since only one study included such data. The timing of
blood sampling for PCT levels varied among the in-
cluded studies. However, for all studies, we considered
the value of the first available PCT sampled during the
diagnostic process.
Conclusions
PCT should not be used as a standalone tool for the dif-
ferential diagnosis between candidemia and bacteremia
due to limited supporting evidence. In this setting, PCT
values seem to be insufficiently discriminative to guide
therapeutic decisions. PCT should be further investi-
gated in antifungal stewardship programs, in association
with other biomarkers or non-culture diagnostic tests.
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